Anavex Life Sciences to Current on the H.C. Wainwright fifth Annual Neuro Views Digital Convention

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Firm”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical firm growing differentiated therapeutics for the remedy of neurodegenerative, neurodevelopmental and neuropsychiatric problems together with Alzheimer’s illness, Parkinson’s illness, Rett syndrome, schizophrenia, and different central nervous system (CNS) illnesses, immediately introduced that Christopher U. Missling, PhD, President and Chief Government Officer of Anavex, will current on the H.C. Wainwright 5^th Annual Neuro Views Digital Convention being held June 27, 2024.

An audio webcast will probably be accessible on demand starting on Thursday, June 27, 2024, at 7:00 a.m. ET via the Buyers part of the Firm’s web site at www.anavex.com.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical firm devoted to the event of novel therapeutics for the remedy of neurodegenerative, neurodevelopmental, and neuropsychiatric problems, together with Alzheimer’s illness, Parkinson’s illness, Rett syndrome, schizophrenia and different central nervous system (CNS) illnesses, ache, and varied forms of most cancers. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), has efficiently accomplished a Section 2a and a Section 2b/3 scientific trial for Alzheimer’s illness, a Section 2 proof-of-concept research in Parkinson’s illness dementia, and each a Section 2 and a Section 3 research in grownup sufferers and one Section 2/3 in pediatric sufferers with Rett syndrome. ANAVEX®2-73 is an orally accessible drug candidate that restores mobile homeostasis by concentrating on SIGMAR1 and muscarinic receptors. Preclinical research demonstrated its potential to halt and/or reverse the course of Alzheimer’s illness. ANAVEX®2-73 additionally exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal fashions, indicating its potential to deal with further CNS problems, together with epilepsy. The Michael J. Fox Basis for Parkinson’s Analysis beforehand awarded Anavex a analysis grant, which totally funded a preclinical research to develop ANAVEX®2-73 for the remedy of Parkinson’s illness. We imagine that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising scientific stage drug candidate demonstrating disease-modifying exercise in opposition to the main hallmarks of Alzheimer’s illness in transgenic (3xTg-AD) mice, together with cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has proven useful results on mitochondrial dysfunction and neuroinflammation. Additional info is obtainable at www.anavex.com. You can too join with the Firm on Twitter,Fb, Instagram, and LinkedIn.

Ahead-Trying Statements

Statements on this press launch that aren’t strictly historic in nature are forward-looking statements. These statements are solely predictions primarily based on present info and expectations and contain plenty of dangers and uncertainties. Precise occasions or outcomes might differ materially from these projected in any of such statements as a consequence of varied components, together with the dangers set forth within the Firm’s most up-to-date Annual Report on Type 10-Okay filed with the SEC. Readers are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date hereof. All forward-looking statements are certified of their entirety by this cautionary assertion and Anavex Life Sciences Corp. undertakes no obligation to revise or replace this press launch to mirror occasions or circumstances after the date hereof.

For Additional Data:
Anavex Life Sciences Corp.
Analysis & Enterprise Growth
Toll-free: 1-844-689-3939
E mail: [email protected]

Buyers:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
E mail: [email protected]